Titration of the Osteocalcin antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,IHC (Paraffin): 1:50-1:100
限制
仅限研究用
状态
Liquid
缓冲液
In 1X PBS, pH 7.4, with 0.09 % sodium azide
储存液
Sodium azide
注意事项
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
-20 °C
储存方法
Aliquot the Osteocalcin antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
BGP antibody, OC antibody, OCN antibody, Bglap1 antibody, Bglap2 antibody, OG1 antibody, mOC-A antibody, Bgp antibody, Bgpr antibody, Bgpra antibody, bgp antibody, LOC792433 antibody, ocn antibody, GLA antibody, BGLAP antibody, PMF1 antibody, bone gamma-carboxyglutamate protein antibody, bone gamma carboxyglutamate protein antibody, bone gamma-carboxyglutamate protein S homeolog antibody, bone gamma-carboxyglutamate (gla) protein antibody, osteocalcin antibody, polyamine-modulated factor 1 antibody, BGLAP antibody, Bglap antibody, bglap.S antibody, bglap antibody, ocn antibody, LOC100529177 antibody, LOC100146589 antibody
背景
Prior to the formation of calcified bone, noncollagenous proteins form in the extracellular bone matrix. Gamma-carboxyglutamic acid residues are formed by vitamin K, vitamin-D regulated calcium binding proteins containing residues of Gla. These residues are essential for the binding of calcium and constitue 1-2 % of total bone protein. Osteocalcin itself binds strongly to apatite and calcium. Production of osteocalcin is expressed late in normal bone development and is characteristic of mature osteoblasts. Regular osteocalcin production has been shown to be linked to the p53 tumor suppressor gene. The p53 gene undergoes rearrangement in a high percentage of osteosarcomas, resulting in loss of its expression. The loss of p53 regulation inhibits further osteocalcin production. The absence of end-point differentiation in bone due to p53 rearrangements and lack of osteocalcin production may contribute to the maintenance of the tumorigenic phenotype in osteosarcomas.